BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Trifan A, Burta O, Tiuca N, Petrisor DC, Lenghel A, Santos J. Efficacy and safety of Gelsectan for diarrhoea-predominant irritable bowel syndrome: A randomised, crossover clinical trial. United European Gastroenterol J 2019;7:1093-101. [PMID: 31662866 DOI: 10.1177/2050640619862721] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
Number Citing Articles
1 Esquena-moret J. A Review of Xyloglucan: Self-Aggregation, Hydrogel Formation, Mucoadhesion and Uses in Medical Devices. Macromol 2022;2:562-590. [DOI: 10.3390/macromol2040037] [Reference Citation Analysis]
2 Pop C, Sporea I, Santos J, Tudor N, Tiuca N. Efficacy and Safety of a Novel Therapeutic of Natural Origin (NTN) in Adult Patients with Lactose Intolerance: A Multicenter, Randomized, Crossover, Double-Blind, Placebo-Controlled Study. Foods 2022;11:2600. [DOI: 10.3390/foods11172600] [Reference Citation Analysis]
3 Stagi S. Medical Devices Made of Substances: The Need for a Change in Approach in Paediatrics. Front Drug Saf Regul 2022;2. [DOI: 10.3389/fdsfr.2022.867143] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Kindt S, Louis H, De Schepper H, Arts J, Caenepeel P, De Looze D, Gerkens A, Holvoet T, Latour P, Mahler T, Mokaddem F, Nullens S, Piessevaux H, Poortmans P, Rasschaert G, Surmont M, Vafa H, Van Malderen K, Vanuytsel T, Wuestenberghs F, Tack J. Belgian consensus on irritable bowel syndrome. AGEB 2022;85:360-382. [DOI: 10.51821/85.2.10100] [Reference Citation Analysis]
5 Gunn D, Abbas Z, Harris HC, Major G, Hoad C, Gowland P, Marciani L, Gill SK, Warren FJ, Rossi M, Remes-Troche JM, Whelan K, Spiller RC. Psyllium reduces inulin-induced colonic gas production in IBS: MRI and in vitro fermentation studies. Gut 2022;71:919-27. [PMID: 34353864 DOI: 10.1136/gutjnl-2021-324784] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
6 Inczefi O, Bacsur P, Resál T, Keresztes C, Molnár T. The Influence of Nutrition on Intestinal Permeability and the Microbiome in Health and Disease. Front Nutr 2022;9:718710. [PMID: 35548572 DOI: 10.3389/fnut.2022.718710] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
7 Ciriza de los Ríos C, Aparicio Cabezudo M, Zatarain Vallés A, Rey E. Practical approach to irritable bowel syndrome-diarrhea beyond low-FODMAP diet. Rev Esp Enferm Dig 2022;114. [DOI: 10.17235/reed.2022.8749/2022] [Reference Citation Analysis]
8 Barbara G, Barbaro MR, Fuschi D, Palombo M, Falangone F, Cremon C, Marasco G, Stanghellini V. Corrigendum: Inflammatory and Microbiota-Related Regulation of the Intestinal Epithelial Barrier. Front Nutr 2021;8:790387. [PMID: 34790692 DOI: 10.3389/fnut.2021.790387] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Fortea M, Albert-Bayo M, Abril-Gil M, Ganda Mall JP, Serra-Ruiz X, Henao-Paez A, Expósito E, González-Castro AM, Guagnozzi D, Lobo B, Alonso-Cotoner C, Santos J. Present and Future Therapeutic Approaches to Barrier Dysfunction. Front Nutr 2021;8:718093. [PMID: 34778332 DOI: 10.3389/fnut.2021.718093] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
10 Chen Z, Shen X, Zhou Q, Zhan Q, Xu X, Chen Q, An F, Sun J. Dietary xylo-oligosaccharide ameliorates colonic mucus microbiota penetration with restored autophagy in interleukin-10 gene-deficient mice. JPEN J Parenter Enteral Nutr 2021. [PMID: 34618377 DOI: 10.1002/jpen.2274] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
11 Barbara G, Barbaro MR, Fuschi D, Palombo M, Falangone F, Cremon C, Marasco G, Stanghellini V. Inflammatory and Microbiota-Related Regulation of the Intestinal Epithelial Barrier. Front Nutr 2021;8:718356. [PMID: 34589512 DOI: 10.3389/fnut.2021.718356] [Cited by in Crossref: 18] [Cited by in F6Publishing: 26] [Article Influence: 9.0] [Reference Citation Analysis]
12 Bellini M, Berti G, Bonfrate L, Ciranni F, Di Ciaula A, Di Ruscio M, Dell'Era A, Lambiase C, Noto A, Pancetti A, Portincasa P, Rettura F. Use of GELSECTAN® in Patients with Irritable Bowel Syndrome (IBS): an Italian Experience. Patient Prefer Adherence 2021;15:1763-74. [PMID: 34413634 DOI: 10.2147/PPA.S318859] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Billings W, Mathur K, Craven HJ, Xu H, Shin A. Potential Benefit With Complementary and Alternative Medicine in Irritable Bowel Syndrome: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2021;19:1538-1553.e14. [PMID: 32961342 DOI: 10.1016/j.cgh.2020.09.035] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
14 Qaseem MF, Shaheen H, Wu A. Cell wall hemicellulose for sustainable industrial utilization. Renewable and Sustainable Energy Reviews 2021;144:110996. [DOI: 10.1016/j.rser.2021.110996] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 12.5] [Reference Citation Analysis]
15 Gaus OV, Livzan MA. Irritable bowel syndrome: what's new? (UEG Week Virtual 2020 materials review). Medicinskij alfavit 2021;1:41-47. [DOI: 10.33667/2078-5631-2021-6-41-47] [Reference Citation Analysis]
16 de Los Rios CC, Falcón BS, Arguelles-Arias F, Pérez E, Teruel C, Geijo F, Rey E. Long-term safety and efficacy study of a medical device containing xyloglucan, pea protein reticulated with tannins and xylo-oligosaccharides, in patients with diarrhoea-predominant irritable bowel syndrome. Therap Adv Gastroenterol 2021;14:17562848211020570. [PMID: 34104216 DOI: 10.1177/17562848211020570] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
17 Giang J, Lan X, Crichton M, Marx W, Marshall S. Efficacy and safety of biophenol-rich nutraceuticals in adults with inflammatory gastrointestinal diseases or irritable bowel syndrome: A systematic literature review and meta-analysis. Nutr Diet 2021. [PMID: 33960587 DOI: 10.1111/1747-0080.12672] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
18 Alonso-Cotoner C, Abril-Gil M, Albert-Bayo M, Mall JG, Expósito E, González-Castro AM, Lobo B, Santos J. The Role of Purported Mucoprotectants in Dealing with Irritable Bowel Syndrome, Functional Diarrhea, and Other Chronic Diarrheal Disorders in Adults. Adv Ther 2021;38:2054-76. [PMID: 33738725 DOI: 10.1007/s12325-021-01676-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
19 Hagan M, Hayee BH, Rodriguez-Mateos A. (Poly)phenols in Inflammatory Bowel Disease and Irritable Bowel Syndrome: A Review. Molecules 2021;26:1843. [PMID: 33805938 DOI: 10.3390/molecules26071843] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
20 Camilleri M. Diagnosis and Treatment of Irritable Bowel Syndrome: A Review. JAMA 2021;325:865-77. [PMID: 33651094 DOI: 10.1001/jama.2020.22532] [Cited by in Crossref: 41] [Cited by in F6Publishing: 48] [Article Influence: 20.5] [Reference Citation Analysis]
21 Colomier E, Algera J, Melchior C. Pharmacological Therapies and Their Clinical Targets in Irritable Bowel Syndrome With Diarrhea. Front Pharmacol 2020;11:629026. [PMID: 33679391 DOI: 10.3389/fphar.2020.629026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
22 Spiller R. Impact of Diet on Symptoms of the Irritable Bowel Syndrome. Nutrients 2021;13:575. [PMID: 33572262 DOI: 10.3390/nu13020575] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
23 Buxeraud J, Faure S, Guerriaud M, Eskenazy D, Sergheraert L, Bruley Des Varannes S. Un nouveau règlement pour les dispositifs médicaux à base de substances. Actualités Pharmaceutiques 2021;60:48-53. [DOI: 10.1016/j.actpha.2020.11.012] [Reference Citation Analysis]
24 Duarte-Silva E, Morais LH, Clarke G, Savino W, Peixoto C. Targeting the Gut Microbiota in Chagas Disease: What Do We Know so Far? Front Microbiol 2020;11:585857. [PMID: 33362735 DOI: 10.3389/fmicb.2020.585857] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
25 Badran M, Mashaqi S, Gozal D. The gut microbiome as a target for adjuvant therapy in obstructive sleep apnea. Expert Opin Ther Targets 2020;24:1263-82. [PMID: 33180654 DOI: 10.1080/14728222.2020.1841749] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]